Journal of Antimicrobial Chemotherapy (2001) 48, 17-28
© 2001 The British Society for Antimicrobial Chemotherapy
Supplement |
Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests
a Department of Medical Microbiology, North Bristol NHS Trust, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB; b Department of Microbiology, City Hospital NHS Trust, Birmingham B18 7QH, UK
Abstract
The purpose of undertaking susceptibility testing, by whatever method, is to attempt to integrate the susceptibility of a population of potential pathogens with the pharmacokinetics of the antimicrobial and, whenever possible, to review this relationship in the light of clinical experience following therapy in clinical trials. Breakpoints are discriminatory antimicrobial concentrations used in the interpretation of results of susceptibility testing to define isolates as susceptible, intermediate or resistant. Clinical, pharmacological and microbiological considerations are important in setting breakpoints, and the ideal mix of these factors is unknown. Different countries have different approaches to this problem but, by and large, these approaches have much in common. This paper attempts to summarize the philosophy of the British Society for Antimicrobial Chemotherapy (BSAC) Working Party in its approach to setting breakpoints and to update the activities of the Working Party since it initially published breakpoints, approximately 10 years ago. The formula outlined by the BSAC Working Party in 1991 has been used to set the breakpoints presented here. The Working Party accepts that in the light of new knowledge, there is a need to reassess how breakpoints are defined, and this paper also summarizes the future activities of the Working Party.
Notes
* Corresponding author. Tel: +44-117-959-5652; Fax: +44-117-959-3154; E-mail: macgowan_a{at}southmead.swest.nhs.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Ruzin, F. W. Immermann, and P. A. Bradford Real-Time PCR and Statistical Analyses of acrAB and ramA Expression in Clinical Isolates of Klebsiella pneumoniae Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3430 - 3432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Pichichero, J. R. Casey, S. L. Block, R. Guttendorf, H. Flanner, D. Markowitz, and S. Clausen Pharmacodynamic Analysis and Clinical Trial of Amoxicillin Sprinkle Administered Once Daily for 7 Days Compared to Penicillin V Potassium Administered Four Times Daily for 10 Days in the Treatment of Tonsillopharyngitis Due to Streptococcus pyogenes in Children Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2512 - 2520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hope, T. Parsons, S. Mushtaq, D. James, and D. M. Livermore Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method J. Antimicrob. Chemother., October 1, 2007; 60(4): 770 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Lo-Ten-Foe, A. M. G. A. de Smet, B. M. W. Diederen, J. A. J. W. Kluytmans, and P. H. J. van Keulen Comparative Evaluation of the VITEK 2, Disk Diffusion, Etest, Broth Microdilution, and Agar Dilution Susceptibility Testing Methods for Colistin in Clinical Isolates, Including Heteroresistant Enterobacter cloacae and Acinetobacter baumannii Strains Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3726 - 3730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Fenoll, L. Aguilar, O. Robledo, M.-J. Gimenez, D. Tarrago, J.-J. Granizo, M. Gimeno, and P. Coronel Influence of the {beta}-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media J. Antimicrob. Chemother., August 1, 2007; 60(2): 323 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Turnidge and D. L. Paterson Setting and Revising Antibacterial Susceptibility Breakpoints Clin. Microbiol. Rev., July 1, 2007; 20(3): 391 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. O'Neill, A. R. Larsen, R. Skov, A. S. Henriksen, and I. Chopra Characterization of the Epidemic European Fusidic Acid-Resistant Impetigo Clone of Staphylococcus aureus J. Clin. Microbiol., May 1, 2007; 45(5): 1505 - 1510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tristram, M. R. Jacobs, and P. C. Appelbaum Antimicrobial Resistance in Haemophilus influenzae Clin. Microbiol. Rev., April 1, 2007; 20(2): 368 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Chopra The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern? J. Antimicrob. Chemother., April 1, 2007; 59(4): 587 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Alou, M. J. Gimenez, D. Sevillano, L. Aguilar, N. Gonzalez, O. Echeverria, M. Torrico, P. Coronel, and J. Prieto Are {beta}-lactam breakpoints adequate to define non-susceptibility for all Haemophilus influenzae resistance phenotypes from a pharmacodynamic point of view? J. Antimicrob. Chemother., April 1, 2007; 59(4): 652 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. W. Govan Multidrug-resistant pulmonary infection in cystic fibrosis - what does 'resistant' mean? J. Med. Microbiol., December 1, 2006; 55(Pt 12): 1615 - 1617. [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Scheetz, K. M. Hurt, G. A. Noskin, and C. M. Oliphant Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens. Am. J. Health Syst. Pharm., July 15, 2006; 63(14): 1346 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Gould, A. Okazaki, and M. B. Avison {beta}-Lactam resistance and {beta}-lactamase expression in clinical Stenotrophomonas maltophilia isolates having defined phylogenetic relationships J. Antimicrob. Chemother., February 1, 2006; 57(2): 199 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ratjen, E. Rietschel, D. Kasel, R. Schwiertz, K. Starke, H. Beier, S. van Koningsbruggen, and H. Grasemann Pharmacokinetics of inhaled colistin in patients with cystic fibrosis J. Antimicrob. Chemother., February 1, 2006; 57(2): 306 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Whitehouse, J. A. Cepeda, R. Shulman, L. Aarons, R. Nalda-Molina, C. Tobin, A. MacGowan, S. Shaw, C. Kibbler, M. Singer, et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill J. Antimicrob. Chemother., March 1, 2005; 55(3): 333 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Griggs, M. M. Johnson, J. A. Frost, T. Humphrey, F. Jorgensen, and L. J. V. Piddock Incidence and Mechanism of Ciprofloxacin Resistance in Campylobacter spp. Isolated from Commercial Poultry Flocks in the United Kingdom before, during, and after Fluoroquinolone Treatment Antimicrob. Agents Chemother., February 1, 2005; 49(2): 699 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Andrews, G. Jevons, N. Brenwald, A. Fraise, and for the BSAC Working Party on Sensitivity Testing Susceptibility testing Pasteurella multocida by BSAC standardized methodology J. Antimicrob. Chemother., November 1, 2004; 54(5): 962 - 964. [Full Text] [PDF]
|
|
|
|
|
|
R. Arguello-Garcia, M. Cruz-Soto, L. Romero-Montoya, and G. Ortega-Pierres Variability and variation in drug susceptibility among Giardia duodenalis isolates and clones exposed to 5-nitroimidazoles and benzimidazoles in vitro J. Antimicrob. Chemother., October 1, 2004; 54(4): 711 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. O'Neill, A. R. Larsen, A. S. Henriksen, and I. Chopra A Fusidic Acid-Resistant Epidemic Strain of Staphylococcus aureus Carries the fusB Determinant, whereas fusA Mutations Are Prevalent in Other Resistant Isolates Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3594 - 3597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Wiegand and S. Burak Effect of inoculum density on susceptibility of Plesiomonas shigelloides to cephalosporins J. Antimicrob. Chemother., August 1, 2004; 54(2): 418 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. W. Scott and T. L. Pitt Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales J. Med. Microbiol., July 1, 2004; 53(7): 609 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Reynolds, N. Potz, M. Colman, A. Williams, D. Livermore, A. MacGowan, and on behalf of the BSAC Extended Working Party on Ba Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme J. Antimicrob. Chemother., June 1, 2004; 53(6): 1018 - 1032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. King, I. Phillips, and K. Kaniga Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria J. Antimicrob. Chemother., May 1, 2004; 53(5): 797 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Reynolds, J. Shackcloth, D. Felmingham, A. MacGowan, and on behalf of the BSAC Extended Working Party on Re Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: the BSAC Respiratory Resistance Surveillance Programme J. Antimicrob. Chemother., December 1, 2003; 52(6): 925 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Reynolds, J. Shackcloth, D. Felmingham, A. MacGowan, and on behalf of the BSAC Extended Working Party on Re Antimicrobial susceptibility of lower respiratory tract pathogens in Great Britain and Ireland 1999-2001 related to demographic and geographical factors: the BSAC Respiratory Resistance Surveillance Programme J. Antimicrob. Chemother., December 1, 2003; 52(6): 931 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Spence and K. J. Towner Frequencies and mechanisms of resistance to moxifloxacin in nosocomial isolates of Acinetobacter baumannii J. Antimicrob. Chemother., October 1, 2003; 52(4): 687 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T L Pitt, M Sparrow, M Warner, and M Stefanidou Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents Thorax, September 1, 2003; 58(9): 794 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kahlmeter, D. F. J. Brown, F. W. Goldstein, A. P. MacGowan, J. W. Mouton, A. Osterlund, A. Rodloff, M. Steinbakk, P. Urbaskova, and A. Vatopoulos European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria J. Antimicrob. Chemother., August 1, 2003; 52(2): 145 - 148. [Full Text] [PDF]
|
|
|
|
|
|
O. Dobay, F. Rozgonyi, E. Hajdu, E. Nagy, M. Knausz, and S. G. B. Amyes Antibiotic susceptibility and serotypes of Streptococcus pneumoniae isolates from Hungary J. Antimicrob. Chemother., April 1, 2003; 51(4): 887 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Tobin, J. Sunderland, A. M. Lovering, and A. P. MacGowan A high performance liquid chromatography (HPLC) assay for linezolid in continuous ambulatory peritoneal dialysis fluid (CAPDF) J. Antimicrob. Chemother., April 1, 2003; 51(4): 1041 - 1042. [Full Text] [PDF]
|
|
|
|
|
|
R. P. SPENCE, K. J. TOWNER, C. J. HENWOOD, D. JAMES, N. WOODFORD, and D. M. LIVERMORE Population structure and antibiotic resistance of Acinetobacter DNA group 2 and 13TU isolates from hospitals in the UK J. Med. Microbiol., December 1, 2002; 51(12): 1107 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. MacKenzie, P. Greig, D. Morrison, G. Edwards, and I. M. Gould Identification and characterization of teicoplanin-intermediate Staphylococcus aureus blood culture isolates in NE Scotland J. Antimicrob. Chemother., November 1, 2002; 50(5): 689 - 697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nzula, P. Vandamme, and J. R. W. Govan Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex J. Antimicrob. Chemother., August 1, 2002; 50(2): 265 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Higgins, A. C. Fluit, D. Milatovic, J. Verhoef, and F.-J. Schmitz Antimicrobial susceptibility of imipenem-resistant Pseudomonas aeruginosa J. Antimicrob. Chemother., August 1, 2002; 50(2): 299 - 301. [Full Text] [PDF]
|
|
|
|
|
|
M. Weinbren and K. Struthers Emergence of Staphylococcus aureus (MRSA) with reduced susceptibility to teicoplanin during therapy J. Antimicrob. Chemother., August 1, 2002; 50(2): 306 - 307. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Andrews and R. Wise Susceptibility testing of Bacillus species J. Antimicrob. Chemother., June 1, 2002; 49(6): 1040 - 1042. [Full Text] [PDF]
|
|
|
|
|
|
C. J. Henwood, T. Gatward, M. Warner, D. James, M. W. Stockdale, R. P. Spence, K. J. Towner, D. M. Livermore, and N. Woodford Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936) J. Antimicrob. Chemother., March 1, 2002; 49(3): 479 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Valtonen, E. Tiula, O. Takkunen, J. T. Backman, and P. J. Neuvonen Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure J. Antimicrob. Chemother., December 1, 2001; 48(6): 881 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Paton, T. Snell, F. X. S. Emmanuel, and R. S. Miles Glycopeptide resistance in an epidemic strain of methicillin-resistant Staphylococcus aureus J. Antimicrob. Chemother., December 1, 2001; 48(6): 941 - 942. [Full Text] [PDF]
|
|